Form 4: Moleculin Biotech CEO Reports Stock Transaction
Insider Transaction (Form 4)
Walter Klemp V, CEO and President and a Director of Moleculin Biotech, Inc., reported multiple transactions in common stock on November 4, 2026.
Summary
- Option exercise/conversion: acquired 57 Common Stock on November 4, 2026; holds 36,217 after (Direct).
- Tax/exercise-price withholding: disposed of 14 Common Stock at $8.46 ($118) on November 4, 2026; holds 36,203 after (Direct).
- Option exercise/conversion: disposed of 57 Restricted Stock Units on November 4, 2026; holds 127,415 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Walter Klemp V — Director, Officer (CEO and President)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-11-04 | Option exercise/conversion | Common Stock | 57 | — | — | 36,217 |
| 2026-11-04 | Tax/exercise-price withholding | Common Stock | 14 | $8 | $118 | 36,203 |
| 2026-11-04 | Option exercise/conversion | Restricted Stock Units | 57 | — | — | 127,415 |
Key Dates
| Date | Description |
|---|---|
| 2026-11-04 | Option exercise/conversion (57 shares) |
| 2026-11-04 | Tax/exercise-price withholding (14 shares) |
| 2026-11-04 | Option exercise/conversion (57 shares) |
Keywords
insider transaction, Form 4, MBRX, Moleculin Biotech, Inc., neutral, Walter Klemp V
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.